Literature DB >> 19787609

25-Gauge sutureless vitrectomy with oblique sclerotomies for the management of retinal detachment in pseudophakic and phakic eyes.

Ziya Kapran1, Nur Acar, Tugrul Altan, Yaprak B Unver, Serap Yurttaser.   

Abstract

PURPOSE: To evaluate the anatomic and functional outcomes of 25-gauge sutureless vitrectomy in primary treatment of noncomplex retinal detachments (RD) in pseudophakic and phakic eyes.
METHODS: In this interventional clinical case series, 23 pseudophakic and 13 phakic eyes with total RDs with proliferative vitreoretinopathy grade A/B underwent primary 25-gauge sutureless vitrectomy with oblique sclerotomies and gas endotamponade. Eyes with minimum follow-up of 6 months were evaluated. Main outcome measures were single surgery and final reattachment rates, complications, and changes in visual acuity (VA).
RESULTS: Mean duration of visual loss was 14.65+/-12.57 and 22.46+/-18.95 days in pseudophakic and phakic eyes, respectively. Eighteen (78.26%) pseudophakic eyes and 12 (92.30%) phakic eyes had macular detachment. In all eyes, 25-gauge sutureless vitrectomy was completed without complication. Mean follow-up period was 11.00+/-6.63 months. Single surgery and final retinal attachment rates were 91.30% and 95.65% in pseudophakic eyes and 61.53% and 84.61% in phakic eyes, respectively (p=0.073, p=0.539). In both groups, mean VA increased significantly at postoperative month 1 (p<0.05) and at the last visit (p<0.001). Transient hypotony was detected in 2 pseudophakic and 3 phakic eyes with spontaneous resolution. Two (15.38%) phakic eyes had cataractous changes.
CONCLUSIONS: In this study, 25-gauge sutureless vitrectomy resulted in higher single surgery and final anatomic success rates in primary treatment of noncomplex RDs in pseudophakic versus phakic eyes, with commensurate increase in VA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19787609     DOI: 10.1177/112067210901900527

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  7 in total

1.  Primary 23-gauge vitreoretinal surgery for rhegmatogenous retinal detachment.

Authors:  Ates Yanyali; Gokhan Celik; Alper Dincyildiz; Fatih Horozoglu; Ahmet F Nohutcu
Journal:  Int J Ophthalmol       Date:  2012-04-18       Impact factor: 1.779

2.  One-year outcomes of 27-gauge versus 25-gauge pars plana vitrectomy for uncomplicated rhegmatogenous retinal detachment repair.

Authors:  Giancarlo Sborgia; Alfredo Niro; Luigi Sborgia; Maria Oliva Grassi; Samuele Gigliola; Mario R Romano; Francesco Boscia; Alessandra Sborgia; Giovanni Alessio
Journal:  Int J Retina Vitreous       Date:  2019-06-04

3.  Comparative Study of 27-Gauge versus 25-Gauge Vitrectomy for the Treatment of Primary Rhegmatogenous Retinal Detachment.

Authors:  Stanislao Rizzo; Silvio Polizzi; Francesco Barca; Tomaso Caporossi; Gianni Virgili
Journal:  J Ophthalmol       Date:  2017-03-04       Impact factor: 1.909

4.  Pars plana vitrectomy for the repair of primary, inferior rhegmatogenous retinal detachment associated to inferior breaks. A comparison of a 25-gauge versus a 20-gauge system.

Authors:  Roberto Dell'Omo; Francesco Barca; H Stevie Tan; Heico M Bijl; Sarit Y Lesnik Oberstein; Marco Mura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-05-17       Impact factor: 3.117

Review 5.  Classifications for Proliferative Vitreoretinopathy (PVR): An Analysis of Their Use in Publications over the Last 15 Years.

Authors:  Salvatore Di Lauro; Mustafa R Kadhim; David G Charteris; J Carlos Pastor
Journal:  J Ophthalmol       Date:  2016-06-27       Impact factor: 1.909

6.  Pseudophakic retinal detachment in young-aged patients.

Authors:  Thomas Laube; Claudia Brockmann; Nils Lehmann; Norbert Bornfeld
Journal:  PLoS One       Date:  2017-08-31       Impact factor: 3.240

7.  Retrospective Comparison of 27-Gauge and 25-Gauge Microincision Vitrectomy Surgery with Silicone Oil for the Treatment of Primary Rhegmatogenous Retinal Detachment.

Authors:  Jie Li; Bo Zhao; Sanmei Liu; Fang Li; Wentao Dong; Jie Zhong
Journal:  J Ophthalmol       Date:  2018-09-16       Impact factor: 1.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.